✦ Lepodisiran & the Lp(a) Long ShotThin moat

The furthest-out bet targets the largest untreated risk factor in cardiology: lipoprotein(a), an inherited particle carried by roughly one person in five, untouched by statins, diet or exercise. Lepodisiran, Lilly's siRNA, silenced it — a 93.9% average reduction in Phase 2, sustained for a year after a single dose¹. The decisive test is ACCLAIM-Lp(a): an estimated 17,300 patients, the largest trial the field has run, measuring whether crushing Lp(a) actually prevents heart attacks and strokes — with completion expected near 2029².

The wager's shape is binary and patient: if outcomes follow the biology, Lilly owns a once-or-twice-yearly injection addressing a risk factor in a billion-plus people — statin economics with biotech pricing. If the hypothesis fails, as cholesterol adjacents sometimes have, the program joins the graveyard of beautiful mechanisms. Novartis's pelacarsen reads out first and will preview the class's fate. Until then this is an option held cheaply against a decade of cardiovascular revenue — watch pelacarsen's result, ACCLAIM's enrollment pace, and any interim analysis the monitors let slip.